117 related articles for article (PubMed ID: 38367405)
1. Integration of on-treatment modified Glasgow prognostic score (mGPS) to improve imaging-based prediction of outcomes in patients with non-small cell lung cancer on immune checkpoint inhibition.
Saal J; Bald T; Eckstein M; Ralser DJ; Brossart P; Ellinger J; Hölzel M; Klümper N
Lung Cancer; 2024 Mar; 189():107505. PubMed ID: 38367405
[TBL] [Abstract][Full Text] [Related]
2. Integrating On-Treatment Modified Glasgow Prognostic Score and Imaging to Predict Response and Outcomes in Metastatic Renal Cell Carcinoma.
Saal J; Bald T; Eckstein M; Ralser DJ; Ritter M; Brossart P; Grünwald V; Hölzel M; Ellinger J; Klümper N
JAMA Oncol; 2023 Aug; 9(8):1048-1055. PubMed ID: 37347489
[TBL] [Abstract][Full Text] [Related]
3. Modified Glasgow Prognostic Score associated with survival in metastatic renal cell carcinoma treated with immune checkpoint inhibitors.
Brown JT; Liu Y; Shabto JM; Martini D; Ravindranathan D; Hitron EE; Russler GA; Caulfield S; Yantorni L; Joshi SS; Kissick H; Ogan K; Nazha B; Carthon BC; Kucuk O; Harris WB; Master VA; Bilen MA
J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34326170
[TBL] [Abstract][Full Text] [Related]
4. On-treatment Modified Glasgow Prognostic Score Provides Predictive Information Complementary to Radiological Staging in Metastatic Urothelial Carcinoma on Immunotherapy.
Saal J; Grünwald V; Bald T; Ritter M; Brossart P; Tomita Y; Hartmann A; Hölzel M; Eckstein M; Klümper N
Eur Urol Oncol; 2024 Jun; 7(3):328-331. PubMed ID: 37996277
[TBL] [Abstract][Full Text] [Related]
5. A comprehensive analysis of Glasgow Prognostic Score (GPS)/the modified Glasgow Prognostic Score (mGPS) on immune checkpoint inhibitor efficacy among patients with advanced cancer.
Zhang Y; Chen S; Chen H; Li W
Cancer Med; 2023 Jan; 12(1):38-48. PubMed ID: 35702873
[TBL] [Abstract][Full Text] [Related]
6. Clinical utility of pretreatment Glasgow prognostic score in non-small-cell lung cancer patients treated with immune checkpoint inhibitors.
Takamori S; Takada K; Shimokawa M; Matsubara T; Fujishita T; Ito K; Toyozawa R; Yamaguchi M; Okamoto T; Yoneshima Y; Tanaka K; Okamoto I; Tagawa T; Mori M
Lung Cancer; 2021 Feb; 152():27-33. PubMed ID: 33341085
[TBL] [Abstract][Full Text] [Related]
7. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
8. Baseline Modified Glasgow Prognostic Score Associated with Survival in Metastatic Urothelial Carcinoma Treated with Immune Checkpoint Inhibitors.
Brown JT; Liu Y; Shabto JM; Martini DJ; Ravindranathan D; Hitron EE; Russler GA; Caulfield S; Yantorni LB; Joshi SS; Kissick H; Ogan K; Harris WB; Carthon BC; Kucuk O; Master VA; Bilen MA
Oncologist; 2021 May; 26(5):397-405. PubMed ID: 33634507
[TBL] [Abstract][Full Text] [Related]
9. Comparison of the Glasgow Prognostic Score (GPS) and the modified Glasgow Prognostic Score (mGPS) in evaluating the prognosis of patients with operable and inoperable non-small cell lung cancer.
Fan H; Shao ZY; Xiao YY; Xie ZH; Chen W; Xie H; Qin GY; Zhao NQ
J Cancer Res Clin Oncol; 2016 Jun; 142(6):1285-97. PubMed ID: 26864695
[TBL] [Abstract][Full Text] [Related]
10. Impact of modified Glasgow prognostic score on predicting prognosis and modification of risk model for patients with metastatic renal cell carcinoma treated with first line tyrosine kinase inhibitor.
Yukihiro K; Teishima J; Goto K; Aoki G; Sekino Y; Hayashi T; Hasegawa Y; Mita K; Kato M; Kajiwara M; Shigeta M; Maruyama S; Kadonishi Y; Fujiwara S; Hinata N
Urol Oncol; 2022 Oct; 40(10):455.e11-455.e18. PubMed ID: 35851184
[TBL] [Abstract][Full Text] [Related]
11. Development and Validation of a Prognostic Model for Patients with Advanced Lung Cancer Treated with the Immune Checkpoint Inhibitor Atezolizumab.
Hopkins AM; Kichenadasse G; Garrett-Mayer E; Karapetis CS; Rowland A; Sorich MJ
Clin Cancer Res; 2020 Jul; 26(13):3280-3286. PubMed ID: 32086341
[TBL] [Abstract][Full Text] [Related]
12. Prognostic role of modified Glasgow Prognostic score in elderly non-small cell lung cancer patients treated with anti-PD-1 antibodies.
Tanaka T; Yoshida T; Masuda K; Takeyasu Y; Shinno Y; Matsumoto Y; Okuma Y; Goto Y; Horinouchi H; Yamamoto N; Ohe Y
Respir Investig; 2023 Jan; 61(1):74-81. PubMed ID: 36460585
[TBL] [Abstract][Full Text] [Related]
13. Definition of a new blood cell count score for early survival prediction for non-small cell lung cancer patients treated with atezolizumab: Integrated analysis of four multicenter clinical trials.
Zhou JG; Wong AH; Wang H; Jin SH; Tan F; Chen YZ; He SS; Shen G; Frey B; Fietkau R; Hecht M; Carr SR; Wang R; Shen B; Schrump DS; Ma H; Gaipl US
Front Immunol; 2022; 13():961926. PubMed ID: 36119066
[TBL] [Abstract][Full Text] [Related]
14. Clinical utility of the pretreatment glasgow prognostic score in patients with advanced inoperable non-small cell lung cancer.
Leung EY; Scott HR; McMillan DC
J Thorac Oncol; 2012 Apr; 7(4):655-62. PubMed ID: 22425914
[TBL] [Abstract][Full Text] [Related]
15. Differential prognostic effect of systemic inflammation in patients with non-small cell lung cancer treated with immunotherapy or chemotherapy: A post hoc analysis of the phase 3 OAK trial.
Cortellini A; Ricciuti B; Borghaei H; Naqash AR; D'Alessio A; Fulgenzi CAM; Addeo A; Banna GL; Pinato DJ
Cancer; 2022 Aug; 128(16):3067-3079. PubMed ID: 35727053
[TBL] [Abstract][Full Text] [Related]
16. Patient-reported outcomes as a prognostic marker of survival in patients with advanced nonsmall cell lung cancer treated with immunotherapy.
Hopkins AM; Wagner J; Kichenadasse G; Modi N; Rowland A; Sorich MJ
Int J Cancer; 2020 Dec; 147(11):3085-3089. PubMed ID: 32492185
[TBL] [Abstract][Full Text] [Related]
17. Modified Glasgow Prognostic Score predicts survival among advanced non-small cell lung carcinoma patients treated with anti-PD1 agents.
Freitas C; Jacob M; Tavares N; Cruz-Martins N; Souto-Moura C; Araújo D; Novais-Bastos H; Santos V; Fernandes G; Magalhães A; Hespanhol V; Queiroga H
Anticancer Drugs; 2021 Jun; 32(5):567-574. PubMed ID: 33661189
[TBL] [Abstract][Full Text] [Related]
18. Prognostic impact of the high-sensitivity modified Glasgow prognostic score in patients with resectable non-small cell lung cancer.
Osugi J; Muto S; Matsumura Y; Higuchi M; Suzuki H; Gotoh M
J Cancer Res Ther; 2016; 12(2):945-51. PubMed ID: 27461679
[TBL] [Abstract][Full Text] [Related]
19. Clinical utility of the Glasgow Prognostic Score in patients undergoing curative nephrectomy for renal clear cell cancer: basis of new prognostic scoring systems.
Lamb GW; Aitchison M; Ramsey S; Housley SL; McMillan DC
Br J Cancer; 2012 Jan; 106(2):279-83. PubMed ID: 22166802
[TBL] [Abstract][Full Text] [Related]
20. Modified Glasgow Prognostic Score is predictive of prognosis for non-small cell lung cancer patients treated with stereotactic body radiation therapy: a retrospective study.
Chen Z; Nonaka H; Onishi H; Nakatani E; Sato Y; Funayama S; Watanabe H; Komiyama T; Kuriyama K; Marino K; Aoki S; Araya M; Tominaga L; Saito R; Maehata Y; Oguri M; Saito M
J Radiat Res; 2021 May; 62(3):457-464. PubMed ID: 33866376
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
